A Clinical Study of Fatty Liver disease.

A Randomized Single Blind Controlled Clinical Study To Evaluate The Safety And Efficacy Of Qurse -e-Ward In Cases Of Tashhamul Kabid (Non Alcoholic Fatty Liver Disease). - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075872

Enrollment

Registered

2024-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Unani Drugs: 1)QURS E WARD 2)AKSEER E JIGAR: EACH PATIENT IS TREATED WITH UNANI FORMULATION WITH DURATION OF 60 DAYS IN THE FORM OF TAB 1. QURS E WARD 3.5G BD WITH WATER

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patient with Pain in Upper Abdomen or Discomfort, Nausea and Vomiting, Anorexia, Tenderness in Hepatic Region. 2)Patient with Grade 1 And Grade 2 Fatty Liver. 3)Patient with Diabetic.

Exclusion criteria

Exclusion criteria: 1)Patient with History of Cardiovascular Diseases, Respiratory Diseases associated Liver Pathology Like Fibrosis, Cirrhosis and Carcinoma. 2)Patient with Hypertension 3)Women with Pregnancy and Lactation. 4)Mentally Retarded Patients. 5)Patient with Grade 3 Fatty Liver.

Design outcomes

Secondary

Measure	Time frame
TO REDUCE SIGN AND SYMPTOMS (ABDOMINAL PAIN NAUSEA AND VOMITING OR BOTH ,HEPATIC TENDERNESS AND ANOREXIA)Timepoint: 15 DYAS	—

Primary

Measure	Time frame
Reduced Fatty Infiltration.Timepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDR MOHAMMADI BEGUM

Govt Nizamia Tibbi College And General Hospital Charminar

ahmedfarhath66@gmail.com9848195067

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026